Patient Education and Clinical Considerations in Multiple Myeloma

EP: 1.Introduction and Pathophysiology of Multiple Myeloma

EP: 2.Epidemiology and Prognosis of Multiple Myeloma

EP: 3.First-line Therapy Options in Multiple Myeloma

EP: 4.Defining Relapse and Switching Therapies in Multiple Myeloma

EP: 5.Key Background Information on Bispecific Antibodies

EP: 6.Linvoseltamab for Patients with Relapsed/Refractory Multiple Myeloma

EP: 7.Optimizing Patient Selection with Bispecific Antibodies in Relpased/Refractory Multiple Myeloma

EP: 8.Dosing Schedules with Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma and Safety Considerations

EP: 9.Logistical Considerations with Bispecific Antibodies

EP: 10.Addressing Unmet Needs in Future Management of Patients with Relapsed/Refractory Multiple Myeloma

Now Viewing

EP: 11.Patient Education and Clinical Considerations in Multiple Myeloma

EP: 12.Ideal Candidates for Bispecific Antibody Therapy

In this AJMC Peer Exchange®, Andrew Yee, MD, provides expert insight into the current and emerging treatment strategies for relapsed/refractory multiple myeloma (RRMM), focusing on how novel immunotherapies are transforming the care landscape. The program opens by outlining key considerations in diagnosing refractory disease, assessing response, and adjusting treatment plans. Yee discusses the importance of individualized patient education, adherence support, and communication with caregivers as essential components of comprehensive multiple myeloma management.

The conversation then delves into the latest clinical data driving therapeutic innovation. Yee reviews pivotal trials that led to the approvals of elranatamab and linvoseltamab, 2 bispecific antibodies targeting BCMA and CD3 that have shown high response rates and durable efficacy in heavily pretreated RRMM populations. He contrasts these therapies with CAR T-cell options, discussing how factors such as patient fitness, prior lines of therapy, and logistical considerations guide treatment selection. The segment also covers adverse event management—particularly cytokine release syndrome and neurotoxicity—and the proactive measures clinicians can take to ensure safety and continuity of care.

The final portion of the discussion focuses on future directions in RRMM therapy. Yee explores how combination regimens involving bispecific antibodies, CAR T therapies, and small molecules may enhance depth and duration of response over the next 5 years. He reflects on how ongoing research, including trials exploring earlier use of immunotherapy and improved manufacturing timelines for CAR T, could further personalize treatment sequencing. Ultimately, the program underscores that innovation in RRMM management is moving toward precision-based, immune-driven, and patient-centered care, where therapeutic choice is guided by both efficacy and quality-of-life considerations.